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Many hematopoietic cell types express CD1d and
are capable of presenting glycolipid antigens to
invariant natural killer T cells (iNKT cells). However,
the question of which cells are the principal pre-
senters of glycolipid antigens in vivo remains contro-
versial, and it has been suggested that this might
vary depending on the structure of a particular glyco-
lipid antigen. Here we have shown that a single type
of cell, the CD8a+ DEC-205+ dendritic cell, was
mainly responsible for capturing and presenting a
variety of different glycolipid antigens, includingmul-
tiple forms of a-galactosylceramide that stimulate
widely divergent cytokine responses. After glycolipid
presentation, these dendritic cells rapidly altered
their expression of various costimulatory and coinhi-
bitory molecules in a manner that was dependent on
the structure of the antigen. These findings show
flexibility in the outcome of two-way communication
between CD8a+ dendritic cells and iNKT cells,
providing a mechanism for biasing toward either
proinflammatory or anti-inflammatory responses.
INTRODUCTION
Natural killer T cells with invariant T cell receptor a chains (iNKT
cells) are a conserved population that recognizes glycolipidantigens bound to CD1d, a lipid antigen-presenting molecule
with structural similarities to major histocompatibility complex
(MHC) class I proteins (Brennan et al., 2013; Rossjohn et al.,
2012). Studies of the prototypical glycolipid antigen of iNKT cells,
an a-galactosylceramide (aGC) known as KRN7000, show the
potential for iNKT cells to activate a range of immune effector
functions in vivo. This occurs both through direct stimulation of
iNKT cell functions and by transactivation of other effectors,
most notably NK cells and dendritic cells (Brennan et al., 2013;
Carnaud et al., 1999; Taraban et al., 2008). Multiple studies
show that this transactivation is influenced by the precise struc-
ture of glycolipid antigens, which has enabled manipulation of
immune responses with structural analogs of aGC (Venkatasw-
amy and Porcelli, 2010). For example, derivatives of aGC con-
taining truncated or unsaturated N-acyl chains induce responses
in which cytokines typically associated with T helper-2 (Th2) cells
predominate, and transactivation of NK cells is limited (Yu et al.,
2005). On the other hand, replacing the O-glycosidic linkage of
aGC with a nonhydrolyzable carbon linker gives a C-glycoside
variant that induces cytokine responses biased toward cyto-
kines characteristic of T helper 1 (Th1) cells, alongwith enhanced
transactivation of NK cells and their secretion of interferon-g
(IFN-g) (Schmieg et al., 2003).
Several models have been put forth to explain how variations
in the structure of glycolipid antigens lead to different outcomes
of iNKT cell activation. Surprisingly, the induction of Th1 cell-
versus Th2 cell-associated cytokines and the extent of NK cell
transactivation do not correlate consistently with the potency
of different aGC analogs, or with the affinity with which they
interact with the T cell receptors (TCRs) of iNKT cells (Im et al.,Immunity 40, 105–116, January 16, 2014 ª2014 The Authors 105
Figure 1. Identification of Cells Mediating Glycolipid Uptake and
Presentation in the Spleen
(A) Structures of aGC C26:0 and a fluorescently tagged form of bGC.
(B) Micewere injected with amixture of bGC-TopFluor and aGCC26:0 (2 nM of
each, i.p.) and spleens were harvested 16 hr later. After staining with mAbs
specific for leukocyte markers, flow cytometry was used to gate on each of the
indicated cell types and MFI for bGC-TopFluor was determined as a measure
of glycolipid uptake (open bars). Staining for total cell surface CD1d expression
is also shown (filled bars). Means ± 1 SD are shown for groups of four animals.
(C) Plots at top show signal for bGC-TopFluor (FL1) in total splenocytes of
representative mice injected i.p. with saline (left) or with 2 nanomoles of bGC-
TopFluor (right). Regions were defined as negative, low, or high for bGC-
TopFluor staining. Plots below show the bGC-TopFluor negative (left), low
(center), and high (right) fractions gated separately and analyzed for DEC-205
expression and aGCC26:0 presentation with the L363mAb. Numbers indicate
frequency of cells in the outlined regions. Representative results of three in-
dependent experiments are shown. See also Figure S1.
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In Vivo Antigen-Presenting Cell for Glycolipids2009; Sullivan et al., 2010; Tyznik et al., 2011; Wu et al., 2011). A
unifying feature of aGC analogs that induce predominantly Th2
cell-associated cytokines is that they are more polar than
KRN7000 and can load directly onto CD1d molecules on the
cell surface (Im et al., 2009; Tyznik et al., 2011). In contrast, gly-
colipids that induce responses that are biased toward Th1 cell106 Immunity 40, 105–116, January 16, 2014 ª2014 The Authorscytokines are more hydrophobic and require intracellular loading
onto CD1d for presentation (Arora et al., 2011; Im et al., 2009).
Because most cells of hematopoietic origin express CD1d
(Brossay et al., 1997), it has been proposed that selective pre-
sentation by different cell types could account for variation in
functional outcomes with different glycolipid antigens (Bezbrad-
ica et al., 2005; Yu et al., 2005). This possibility was supported by
a recent study using lineage-specific conditional deletion of
Cd1d gene expression, which identified presentation by different
types of antigen-presenting cells (APCs) as amajor factor under-
lying the cytokine biasing properties of different aGC variants
(Bai et al., 2012). However, other studies yielded different
conclusions, identifying pharmacokinetic properties of the
glycolipids or localization of CD1d molecules containing bound
glycolipids to different membrane microdomains as major deter-
minants of cytokine skewing in the response to iNKT cell activa-
tion (Im et al., 2009; Sullivan et al., 2010).
In the current study, we reassessed the presentation of various
forms of aGC in vivo to identify the predominant APCs involved in
presentation of diverse glycolipid antigens. By visualizing glyco-
lipid antigen presentation directly with monoclonal antibodies
specific for complexes of aGC bound to CD1d, we showed
that the CD8a+DEC-205+ subset of dendritic cells was the major
APC in the spleen for a range of aGC analogs, irrespective of
their chemical structures and cytokine biasing activities. Interac-
tion of CD8a+ dendritic cells (DCs) with iNKT cells during presen-
tation of Th1 cell-biasing versus Th2 cell-biasing glycolipid
antigens led to markedly different changes in expression of cos-
timulatory and coinhibitory molecules on these cells, including a
reciprocal regulation of CD70 and PD-L2 that was linked to
enhancing or suppressing IFN-g production by transactivated
NK cells. Our findings suggest that, rather than presentation by
alternate types of APCs, the rapid change in cell surface mole-
cule expression by CD8a+ DCs in response to different chemical
forms of aGC is the principal mechanism regulating bystander
cell transactivation and proinflammatory versus anti-inflamma-
tory outcomes following iNKT cell activation.
RESULTS
Glycolipid Uptake and Presentation by Candidate APCs
To identify the cells capable of taking up and potentially pre-
senting glycolipid antigens, we used a fluorescent derivative of
b-galactosylceramide (bGC-TopFluor), which has a general
overall structural similarity to aGC (Figure 1A) (Boldyrev et al.,
2007). After coinjection intraperitoneally (i.p.) of mice with
bGC-TopFluor and the CD1d-presented iNKT cell agonist aGC
C26:0, splenocytes were harvested and stained withmonoclonal
antibodies (mAbs) specific for cell surface markers to allow
selective gating on each of the major leukocyte subsets. The
cells were also stained with a mAb specific for CD1d, or with
mAb L363 that selectively recognizes complexes formed by
the binding of aGC to CD1d (Yu et al., 2007, 2011). Phagocytic
cells including macrophages, DCs, monocytes, and neutrophils
were all efficient at taking up the bGC probe, while only minimal
uptake was seen with most lymphoid subsets regardless of their
CD1d expression (Figure 1B; Figure S1). Gating on the relatively
small fraction of highly bGC+ cells revealed that 25% of these
also stained with L363, indicating aGC presentation (Figure 1C).
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Figure 2. Direct Visualization of Glycolipid Uptake and Presentation in the Spleen
Confocal micrographs of splenic sections from aGC C26:0-treated mice (12 hr after i.p. injection) showing showing uptake of bGC-TopFluor or immunofluo-
rescent staining for various phenotypic markers in red (top row) and mAb L363 in green (middle row). Bottom row shows merge of red and green images above
each panel. Pearson correlation coefficients (R2) for colocalization of red and green signals are shown below merged images. Dashed white lines outline the
marginal zone separating T cell rich areas from the B cell rich follicles. Images were acquired using a 403 objective with digital zoom of approximately 2- to 3-fold.
Scale bars at the top left of micrographs represent 50 mm. See also Figure S2.
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showed L363 binding, and no significant L363 binding was
detected among bGC cells. Further phenotypic analysis indi-
cated that nearly all L363-positive cells expressed the mannose
receptor DEC-205 and CD11c, identifying them as a subpopula-
tion of DCs (Figure 1C; data not shown).
Direct visualization of glycolipid uptake and presentation was
achieved with confocal microscopy of splenic cryosections.
This showed that L363 staining colocalized partially with bGC-
TopFluor, consistent with presentation of aGC by a subset of
glycolipid engulfing cells (Figure 2). Interestingly, although
CD1d colocalized with both B220+ B cells and CD11c+ DCs (Fig-
ureS2), stainingwith L363was largely excluded fromBcell areas.
Instead, the majority of L363 staining was in the marginal zones
and T cell areas of the splenic white pulp, where it colocalized
with staining for CD11c and DEC-205. Taken together, these
findings indicated that presentation of aGC C26:0 in the spleen
following systemic injection was restrictedmainly to a population
of DEC-205+ DCs that avidly take up exogenous glycolipids.
Identification of In Vivo APCs for aGC Analogs
We focused on presentation of three well-characterized iNKT
cell glycolipid antigens, aGC C26:0, aGC C20:2, and a-C-GC(C-glycoside), which are representative of three different types
of cytokine-biasing analogs. Whereas aGC C26:0 induces a
mixed response with both Th1 cell- and Th2 cell-associated
cytokines, aGC C20:2 stimulates a Th2 cell cytokine pattern
and a-C-GC gives a Th1 cell-biased pattern (Figures S3A and
S3B). By using flow cytometry, we examined the in vivo presen-
tation of these aGC analogs by different splenic subsets.
CD11cHi DCs showed strong acquisition of L363 staining, which
wasmuch higher in CD8a+ compared to the CD8aDCs (Figures
3A and 3B). In contrast, L363 staining was not detected on B
cells following injection of any of the glycolipid antigens,
including the marginal zone B cells, which showed extremely
high CD1d expression. Similarly, presentation was not detected
on B220+ CD11cLo plasmacytoid DCs, Ly6CHi and Ly6CLo
monocytes, or Ly6G+ neutrophils. Thus, based on direct detec-
tion of glycolipid antigens in complex with CD1d on the cell sur-
face, CD8a+ DCs appeared to be themain APC for all three forms
of aGC, regardless of their cytokine-biasing properties.
Previous in vitro studies have shown that the kinetics of glyco-
lipid uptake and presentation can vary widely for different aGC
analogs, and that this correlates with the type of responses
generated (Im et al., 2009; Sullivan et al., 2010). To examine
this correlation in vivo, the kinetics of glycolipid presentationImmunity 40, 105–116, January 16, 2014 ª2014 The Authors 107
Figure 3. In Vivo Presenting Cells for Functionally Distinct aGC Analogs
(A) Flow cytometry of splenic subsets to analyze L363 staining following glycolipid antigen injection. Multiparameter staining for cell-type-specific markers and
gating strategy for each population is illustrated by plots on the left. Histograms show the extent of glycolipid presentation based on L363 staining in each cell type
from spleens of mice injected previously with aGC analogs that induce different cytokine profiles (filled histograms) or vehicle (open histograms). L363 staining is
shown for time points giving maximal signals for each glycolipid (24, 48, and 2 hr after injection for aGC C26:0, a-C-GC, and aGC C20:2, respectively). Fo B,
follicular B cells; MZB, marginal zone B cells; pDC, plasmacytoid DCs; Neu, neutrophils.
(B) Fold increase in L363 (MFI) over vehicle-injected control mice at the time of peak L363 staining for each of the aGC glycolipids. Data shown are means ±
SD, ****p < 0.0001 for comparison with vehicle control (ANOVA with Holm-Sidak test).
(C) In vivo kinetics of aGC presentation by B cell and DC subsets based on MFI of L363 staining of splenocytes from animals treated as in (A). Symbols indicate
aGC C26:0 (solid squares), a-C-GC (open squares), or aGC C20:2 (solid circles). Dashed line indicates L363 staining of cells from animals receiving vehicle
control. Data shown are means ± SEM.
(legend continued on next page)
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In Vivo Antigen-Presenting Cell for Glycolipidsby CD8a+ and CD8a DCs, follicular B cells and marginal zone
B cells were monitored with the L363 mAb (Figure 3C). This
confirmed the rapid presentation of aGC C20:2 by CD8a+ DCs
and to a lower extent by CD8a DCs. This presentation was
maximal in the spleen by 2 hr after aGC C20:2 injection and
then declined rapidly. Both aGC C26:0 and a-C-GC analogs
showed slower kinetics of presentation, peaking at 12 to 24 hr
and remaining elevated at the latest time points examined (Fig-
ure 3C; Figure S3C). In contrast to DCs, no L363 staining was
observed on B cells at any time point.
In situ visualization of CD1d molecules containing bound aGC
C20:2 or a-C-GC in splenic cryosections by using L363 showed
that these failed to colocalize with B220, but strongly colocal-
ized with CD11c (Figure 3D). We also used mice expressing a
fusion protein of green fluorescent protein linked to the chemo-
kine receptor CXCR3 (CX3CR1-GFP) to clearly visualize mono-
cytes and macrophages (Swirski et al., 2009), revealing a lack
of correlation between GFP-positive and L363-positive cells
(Figures S3E and S3F). These findings reinforced our conclusion
that CD8a+ DCs were the predominant APCs for a range of
structurally and functionally distinct glycolipid antigens irrespec-
tive of their Th1 cell or Th2 cell cytokine-biased responses. We
also found that complexes of CD1d and aGC containing
different aGC analogs, formed in vivo on CD8a+ DCs, showed
different sensitivity to detergent extraction from the plasma
membrane (Figure S3D). This finding extends our earlier
in vitro observations that correlate the amount of plasma mem-
brane lipid raft localization of CD1d molecules containing bound
aGC glycolipids with functional biasing of iNKT cell responses
(Arora et al., 2011).
Requirement for CD8a+ DCs for Efficient Glycolipid
Presentation
To further assess the efficiency of aGC presentation by various
cell types, we carried out functional assays of the ability of
various populations of APCs purified from the spleens of aGC
C20:2 injected mice to stimulate normal iNKT cells in culture.
By using CD69 upregulation as a sensitive indicator of iNKT
cell activation, we observed the strongest activation with purified
CD8a+ DCs. A lower level of CD69 induction was seen with
CD8a DCs, and little or none by using purified B cell subsets
as APCs (Figure 4A). These findings closely recapitulated the
pattern of presentation observed with L363 mAb staining (Fig-
ure 3B). Very similar results were obtained with other aGC
analogs with different cytokine biasing properties with this
experimental approach when assessing either upregulation of
iNKT cell activation markers (CD69 or CD25) or cytokine produc-
tion (Figures S4A–S4D).
Additional in vitro studies demonstrated the potent APC func-
tion of DCs for aGC C26:0 and other functionally distinct aGC
analogs, while also showing that B cells lacked this ability. In
one set of experiments, we specifically depleted DCs (CD11c+
cells) and B cells (CD19+ cells) from splenocyte suspensions
and then evaluated their ability to stimulate iNKT cell responses(D) Splenic cryosections stained for L363 (red), B220 (blue), and CD11c (green
a-C-GC C26:0 (24 hr after injection). For merged images, R2 values are prov
50 mm. Representative results are shown from at least three independent ex
also Figure S3.in vitro to aGC C26:0 or aGC C20:2. Compared to B cell deple-
tion, the IFN-g and interleukin-4 (IL-4) responses to both glyco-
lipids were markedly reduced with DC depletion (Figure 4B).
Similar studies using depletion of CD11b+ cells, which include
monocytes and a majority of macrophages, showed little or no
reduction in responses (Figure S4E). To compare the presenta-
tion by DCs and B cells directly, these populations were isolated
from naive spleens, pulsed in vitro with either aGCC26:0 or aGC
C20:2, or with another analog that induces a Th2 cell cytokine
bias (aGC C10:0), and then cultured with NK1.1+ splenic cells
(i.e., iNKT and NK cells) (Figure 4C). With all three glycolipids,
there was markedly higher stimulation of IFN-g and IL-4 secre-
tion with CD11c+ DCs as APCs compared to CD19+ B cells.
Experiments carried out in vivo with purified APC populations
treated ex vivowith glycolipid antigens showed the same general
pattern (Figure 4D). In this case, we injected mice with identical
numbers of purified CD19+ B cells, CD8a DCs, or CD8a+ DCs
after pulsing them with aGC C26:0 or aGC C20:2. Analysis of
serum cytokine secretion showed that CD8a+ DCs were the
most potent inducers of IFN-g for both glycolipid antigens.
Taken together, these experiments indicated that CD8a+ DCs
are the predominant APCs, even for glycolipids that induce a
strong bias toward production of Th2 cell-associated cytokines.
We next sought to investigate the extent to which the CD8a+
DCs were required for glycolipid antigen presentation in vivo
by taking advantage of mice with deletion of the gene encoding
the transcription factor Batf3 (Batf3/ mice). These mice lack
CD8a+ DCs and have few if any other immunological defects
(Hildner et al., 2008). Assessment of iNKT cell frequencies in
Batf3/mice showed no evidence of defects in iNKT selection
and development (Figure 5A), and comparison of in vitro re-
sponses of WT and Batf3/splenocytes to stimulation by
aGC-pulsedWTBMDCs indicated that functionality of iNKT cells
was not compromised in Batf3/ mice (Figure S5A). However,
synthetic aGC analogs induced diminished cytokine responses
when injected into Batf3/ mice regardless of the type of aGC
used (Figure 5B), indicating a requirement for CD8a+ DCs for
efficient presentation. The weak IFN-g responses observed in
WT mice to b-glucosylceramide, a candidate self-glycolipid
ligand of iNKT cells (Brennan et al., 2013), were also reduced
in Batf3/mice (Figure S5B).
The Gram-positive pathogenic bacterium Streptococcus
pneumoniae is known to contain an a-glycosyl diacyl glycerol
glycolipid antigen that is presented by CD1d to iNKT cells, and
efficient clearance of this infection in mice requires iNKT cells
(Kinjo et al., 2011). To investigate whether microbial glycolipid
antigen presentation also required CD8a+ DCs in the setting
of infection, we compared the lung burdens of Batf3/and
WT mice after intranasal infection with S. pneumoniae. The
Batf3/mice displayed higher bacterial burdens in their lungs
(Figure 5C), which was associated with increased neutrophil
migration to this site (Figure 5D). This reduction in bacterial
clearance correlated with fewer IFN-g producing iNKT cells
in the spleens of infected mice (Figure 5E), indicating that) from mice injected previously with the aGC C20:2 (2 hr after injection) or
ided as an index of colocalization of the two signals. Scale bars indicate
periments with analysis of four animals per group in each experiment. See
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Figure 4. Unique Role of CD8a+ DCs in Glycolipid Antigen Presentation
(A) Induction of CD69 on iNKT cells showed predominant APC function for CD8a+ DCs. Flow cytometry sorting was used to purify MZB, FoB, CD8a+, and CD8a
DCs from aGC C20:2 treated mice at 2 hr after glycolipid administration. CD19 and CD11c depleted splenocytes were used as responder cells. Plots show
staining with aGC loaded CD1d tetramers and anti-CD69 after 18 hr of coculture for cultures with 3 3 105 APCs. The graph summarizes results with various
numbers of APCs. *p < 0.05.
(B) Splenocytes were subjected to immunomagnetic depletion of either CD19 (white squares) or CD11c (black squares) positive cells, or mock depleted (black
triangles), and then cultured with various concentrations of aGC C26:0 (left) or aGC C20:2 (right). IFN-g and IL-4 were quantitated in culture supernatants by
ELISA after 16 hr. p < 0.0001 for CD11c+ versus CD19+ depleted; NS for CD19+ versus mock depleted.
(C) Purified CD19+ (white symbols) and CD11c+ (filled symbols) splenocytes were pulsed with different concentrations of three different aGC analogs. After
extensivewashing, purified NK1.1+ spleen cells (enriched20 fold for NK and iNKT cells) were added. Supernatants were collected after 18 hr, and IFN-g and IL-4
were quantitated by ELISA. p < 0.001 for CD11c+ versus CD19+ APCs for all glycolipids tested.
(D) Purified CD19+ (filled circles), CD8a+ DCs (Filled squares), and CD8a DCs (white squares) were pulsed with 100 nM of aGC analogs for 1 hr.
Following extensive washing, 1 3 106 of these ex vivo glycolipid pulsed cells were injected i.v., and blood samples were collected at various time
(legend continued on next page)
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and for rapid generation of protective immunity to this bacterium.
We have also shown previously that modifying live Mycobac-
terium bovis BCG bacilli by incorporation of aGC enhances its
vaccine efficacy against Mycobacterium tuberculosis infection
(Venkataswamy et al., 2009). By using this approach, we
compared serum cytokines in response to i.p. administration of
BCG modified by incorporation of either aGC C26:0 or aGC
C20:2. In both cases, serum cytokine responses were reduced
in Batf3/mice compared toWT animals (Figure 5F), reinforcing
the role of CD8a+ DCs in efficient glycolipid antigen presentation.
Modulation of Accessory Molecules on CD8a+ DCs
The outcomes of cellular interactions during immune responses
are controlled to a great extent by costimulatory and coinhibitory
proteins, which are inducible on APCs in a regulated manner.
This raised the possibility that different analogs of aGC might
induce different patterns of costimulatory or coinhibitory pro-
teins on the surface of CD8a+ DCs. We therefore analyzed
changes in expression of multiple costimulatory or coinhibitory
molecules by CD8a+ DCs over a 3 day period after injection of
mice with either aGC C26:0, C20:2 or C-glycoside. Although
some of these molecules (CD40 and CD80) showed a similar
upregulation with all three of the glycolipid antigens, others
including CD70, Rae-1, and CD86 showed prominent upregula-
tion only with the glycolipids that induced strong Th1 cell-asso-
ciated cytokine responses. Conversely, the coinhibitory proteins
PD-L1 and PD-L2 were upregulated most prominently on DCs
presenting aGC C20:2 that induces Th2 cell cytokine-biased re-
sponses (Figure 6A; Figure S6A). Modulation of costimulatory
and coinhibitory molecules in response to iNKT cell agonists
were seen almost exclusively on CD8a+ DC, with little change
in expression on CD8a DCs, plasmacytoid DCs or B cells (Fig-
ure S6B). All of these alterations appeared to be dependent on
iNKT cells because they did not occur in Tcra-Jtm1Tgi mice
(commonly referred as Ja18/) lacking iNKT cells (Figure S6C;
additional data not shown). In addition, we transferred purified
CD11c+ DCs from Cd1d / and WT animals into WT hosts
and analyzed CD70 expression after glycolipid administration.
This showed greater induction of CD70 on transferred WT
CD8a+ DC compared to transferred Cd1d / DCs (Figure S6D),
suggesting involvement of a direct CD1d-dependent interaction
between iNKT cells and APCs in this process.
The observed patterns of modulation of CD70, Rae-1, PD-L1,
and PD-L2 by CD8a+ DCs provided a plausible mechanism for
controlling the cytokine-biasing activities seen with different
structural analogs of aGC. Thus, a model can be proposed in
which the reciprocal modulation of costimulatory and coinhibi-
tory molecules on CD8a+ DCs leads to differences in the amount
of transactivation of other innate effectors such as NK cells
(Figure 6B). We tested this by studying the roles of PD-1, PD-
L1, PD-L2, and CD70 in modulating cytokine responses stimu-
lated by different aGC analogs. For PD-1 ligands, this was
done by measuring serum cytokine responses to injections ofpoints for measurement of serum IFN-g. Differences were significant for CD8
and p < 0.01 with aGC C20:2). All graphs show means ± SD for triplicate samp
comparison test. Representative results of two (B and C) or three (A and D) inde
also Figure S4.aGC analogs in PD-1, PD-L1, and PD-L2 deficient mice. This
indicated a major role for PD-L2 but not PD-L1 interactions in
modulating iNKT cell dependent cytokine responses to reinforce
the bias toward Th2 cell cytokines induced by aGC C20:2 (Fig-
ure 6C). Thus, PD-L2 signaling had a major effect on dampening
IFN-g production stimulated by aGC C20:2, whereas this was
much less evident for aGC C26:0 and absent for a-C-GC. While
the proportion of NK cells expressing IFN-g increased signifi-
cantly in mice genetically ablated of PD-1 and PD-L2 molecules
in response to aGC C26:0 (Figure S6G), serum IL-12 did not in-
crease relative to WT animals in mice lacking PD-1, PD-L1, or
PD-L2 receiving this glycolipid (Figure S6F), suggesting that
the mechanism for this did not involve an increase in availability
of IL-12. In contrast to the PD-1 signaling effects, a reciprocal
role was demonstrated for CD70 in experiments with treatment
of mice with anti-CD70 blocking antibodies prior to glycolipid
administration. Consistent with the proposed model, blockade
of CD70 reduced IFN-g secretion by aGC C26:0 and a-C-GC,
but had no significant effect on either IL-12 or IL-4 production
stimulated by these analogs or on the predominantly Th2 cell-
associated cytokine responses induced by aGC C20:2 (Figures
6D and 6E; Figure S6E). Overall, our results demonstrate the
central role of CD8a+ DCs in the presentation of a range of
different glycolipid antigens and define a mechanism by which
these APCs control the outcome of iNKT cell activation through
the modulation of cell surface costimulatory molecules.
DISCUSSION
CD1d iswidely expressed by various hematopoietic cells and the
relative importance of different cell types in glycolipid antigen
presentation in vivo remains ambiguous. Previous studies have
suggested that the type of APC involved in glycolipid antigen re-
sponses might vary depending on the structure of the glycolipid
(Bai et al., 2012; Bezbradica et al., 2005; Moody et al., 2002),
leading to major differences in cytokine responses. Here we
have reexamined these issues by using a variety of approaches
to track glycolipid uptake and presentation. Our results identified
CD8a+DEC-205+ DCs as the key APCs for a range of structurally
different glycolipid antigens and suggested a mechanism for
control of iNKT cell responses through the modulation of costi-
mulatory and coinhibitory molecules on these DCs.
Most phagocytic cells showed strong uptake of a fluorescent
glycolipid probe, which might reflect either increased rates of
bulk extracellular fluid uptake or receptor-mediated endocytosis
(Freigang et al., 2012; van den Elzen et al., 2005). Macrophages
are known to express CD1d, although relatively weakly, and are
likely to interact with iNKT cells. Indeed, recent studies have
provided evidence for involvement of macrophages glycolipid
capture and initial antigen presentation events in iNKT cell re-
sponses (Barral et al., 2010; Barral et al., 2012; Lee et al.,
2010). The presenting function of macrophage in those studies,
as opposed to the predominance of CD8a+ DCs in our experi-
ments, might be due to the use of particulate forms of glycolipida+ and CD8a DCs compared to CD19+ cells (p < 0.001 with aGC C26:0
les, and statistical analyses used two-way ANOVA with Holm-Sidak multiple
pendent experiments with sample size of four mice per group are shown. See
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Figure 5. Requirement for CD8a+ DCs for Presentation of Synthetic and Natural Glycolipid Antigens
(A) Frequency of iNKT cells in Batf3/ and WT naive mice. Representative dot plots show viable B220 cells gated for TCRb and aGC-loaded CD1d tetramers.
Bar graph shows mean ± SD for frequencies of iNKT cells in groups of four mice (NS, not significant; Student’s t test).
(B) Comparison of WT and Batf3/mice for serum cytokine responses to five synthetic glycolipid antigens. All mice were injected i.p. with glycolipids (2 nM for
aGC C26:0, a-C-GC, aGC C20:2; 10 nM for aGC C10:0, aGC C8:0). Serum was collected at the time points indicated for measurement of IFN-g and IL-4 (values
for IL-4 are shown only for 2 hr after glycolipid injection). **p < 0.01, ***p < 0.001, ****p < 0.0001 (two-way ANOVA with Holm-Sidak correction).
(C) WT andBatf3/mice on the 129/SJ backgroundwere infected intranasally with 13 106 Streptococcus pneumoniae URF918. Bacterial counts in the lungs on
day 2 are shown. *p < 0.05 (Student’s t test).
(D) Neutrophil infiltration in the lungs as determined by flow cytometry. Mice were sacrificed 2 days after intranasal S. pneumoniae infection, and the frequency of
Ly6G+ CD11b+ cells as a percentage of total cells in lung suspensions was determined by flow cytometry. **p < 0.01 (Student’s t test).
(E) Analysis by flow cytometry of production of IFN-g by splenic iNKT cells 6 hr after S. pneumonia infection. *p < 0.05 (Student’s t test).
(F) Comparison of WT and Batf3/mice for serum cytokine responses to BCGmodified by incorporation of synthetic glycolipid antigens. Mice were injected i.p.
with 53 106 bacteria and serum cytokines were analyzed. Representative results of three independent experiments with four animals per group per experiment
are shown. For the CFU counting experiment seven mice per group per experiment were used. All data are means ± SEM. **p < 0.01 and ****p < 0.0001 (two way
ANOVA, Holm-Sidak test). See also Figure S5.
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Figure 6. Modulation of Cell Surface Costimulatory and Coinhibitory Molecules on CD8a+ DCs following iNKT Cell Antigen Recognition
(A) Splenic CD8a+ DCs (CD11c+ CD8a+) were analyzed by flow cytometry for the indicated cell surfacemolecules at various times following i.p. injection of 2 nMof
each aGC analog (filled squares, aGC C26:0; open squares, a-C-GC; blue filled circles, aGC C20:2). Changes in cell surface expression of costimulatory and
coinhibitory molecules are shown as the fold increase compared to mice injected with vehicle only. Data shown are means ± SD for groups of three mice.
(B) Model for regulation of NK cell transactivation leading to cytokine biasing of iNKT cell-dependent responses through modulation of costimulatory and
coinhibitory proteins on APCs.
(C) Peak serum cytokines following i.p. injection of aGC glycolipid antigens into WT or mice with genetic ablation of PD-1, PD-L1, or PD-L2 (Cd279/,
Pdcd1lg2/,Pdcd1lg2/). The indicated glycolipids (aGCC26:0, a-C-GC, or aGCC20:2) were injected i.p. (2 nM/mouse). IFN-gwasmeasured at 24 hr (for aGC
C26:0 and a-C-GC), or at 12 hr for aGC C20:2. IL-4 was measured at 2 hr after glycolipid injection for all analogs. Data are shown as means ± SD for groups of
three mice, calculated as percent of WT response for each aGC analog.
(D) Effects of in vivo pretreatment of WT mice with anti-CD70 blocking antibodies (open symbols and bars) compared to isotype matched control antibody (filled
symbols and bars). Mice received 200 mg of anti-CD70 or isotype matched control antibody i.p., and 16 hr later were injected with aGC C26:0 (2 nM i.p.). Serum
cytokines were measured at the indicated times after glycolipid injection for IFN-g, and at 2 hr for IL-4 or 8 hr for IL-12.
(E) For a-C-GC and aGCC20:2 glycolipid agonists, isotype control (filled bars), and anti-CD70 (open bars) treated groups are compared for serum IL-4 and IFN-g
responses. IFN-g was measured at 24 hr for a-C-GC and 12 hr for aGC C20:2 agonists, and IL-4 was measured at 2 hr in both cases. Representative results of
three independent experimentswith fourmice per group per experiment are shown. All data aremeans ±SD. For (C), (D), and (E): *p < 0.05, **p < 0.01, ***p < 0.001;
NS, not significant (two-way ANOVA with Holm-Sidak correction). See also Figure S6.
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silica-based particles (Barral et al., 2010) requiring macrophages
for efficient capture and processing. This appears not to berequired for the free glycolipid antigens we have studied, nor
for the two bacterially delivered antigens we have employed. In
addition, studies showing presentation by macrophages haveImmunity 40, 105–116, January 16, 2014 ª2014 The Authors 113
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detect activation. These effects might be more sensitive indica-
tors of activation than cytokine production or transactivation of
NK cells, which are the main end points in our experiments.
Thus, while presentation by macrophages is likely to occur in
some contexts, our results identified a dominant role for
CD8a+ DCs at least for a subset of glycolipid antigens and for
certain types of iNKT cell responses. Of note, another recent
study arrived at a similar conclusion regarding the predominance
of DCs in presentation of aGC and S. pneumonia to iNKT cells
in vivo (King et al., 2013).
A striking finding of our experiments was that the predomi-
nance of CD8a+ DCs as APCs was observed with multiple
different forms of aGC, including those that induce either a
bias toward Th1 cell or Th2 cell-associated cytokine responses.
Our results in Batf3/ mice also indicated a predominant and
nonredundant role for CD8a+ DCs in CD1d-mediated presenta-
tion. These results suggest different conclusions than those of a
recent study in which Cd1d1flox/flox mice were used to ablate
expression of CD1d in DCs, B cells, and macrophages to assess
the role of these cells in presentation of aGC variants (Bai et al.,
2012). Using this approach, it was concluded that forms of aGC
that induce a bias toward Th2 cell-associated cytokines can be
presented by either DCs or B cells, and that preferential presen-
tation by B cells accounts for the altered cytokine pattern seen
with these agonists. Like those investigators, we also observed
partial maintenance of IL-4 responses to glycolipids of this
type in the absence of CD8+ DCs (i.e., in Batf3/mice in our
case; see Figure 5B). Overall, the results are consistent with a
limited ability of other CD1d-positive cells distinct from DCs to
present aGC to iNKT cells. However, in the normal situation
with CD8a+ DCs present, our data suggest that this alternative
APC function of B cells or other types of CD1d expressing cells
is active at a relatively low level and might not contribute signif-
icantly to iNKT cell responses.
Taken together, our results appear inconsistent with a central
role for alternate types of APCs in generating the functionally
different outcomes following iNKT cell activation, at least for
the selected range of antigens we have studied. Instead, we pro-
pose that there is amore subtlemechanism operating at the sub-
cellular level that is mainly responsible for the selective induction
of the so-called Th1 cell- and Th2 cell-associated cytokine-
biased responses. Whereas efforts to attribute cytokine-biasing
effects of glycolipid antigens to variations in DC-derived cyto-
kines have led to conflicting results (Forestier et al., 2007; Miya-
moto et al., 2001), we found in a previous study that induction of
NK cell transactivation and sustained IFN-g secretion correlates
with the extent to which different aGC analogs are presented by
CD1d molecules localized in lipid raft microdomains on the APC
plasma membrane (Im et al., 2009; Tyznik et al., 2011). This sug-
gests parallels with MHC class II-restricted T cell responses,
which have also been found to be regulated by lipid raft-depen-
dent signaling through peptide-MHC II complexes on DCs
(Meyer zum Bueschenfelde et al., 2004). We hypothesize that
recognition by iNKT cells of lipid raft localized CD1d molecules
containing bound aGC glycolipids induce a different intracellular
signaling cascade compared with recognition of non-lipid raft
localized CD1d molecules, thus leading to the markedly diver-
gent changes in expression of cell surface and secreted mole-114 Immunity 40, 105–116, January 16, 2014 ª2014 The Authorscules by CD8a+ DCs. Consistent with this, we found that
remodeling of the costimulatory and coinhibitory molecule pro-
files on APCs could provide a mechanism for the contrasting re-
sponses to different aGC analogs. Although the transactivation
of NK cells and other relevant cells is likely to be influenced by
multiple factors (Bricard et al., 2010; Brigl et al., 2003; Lind
et al., 2009), our data suggest that changes in CD70 expression
induced by iNKT cells might transactivate NK cells directly
through interactionwith CD27. In addition, selective upregulation
of Rae-1 and CD86 by glycolipid antigens that stimulate strong
Th1 cell-associated cytokines could potentially synergize with
activating signals from CD27-CD70 interactions through binding
to their cognate receptors NKG2D and CD28, which are both ex-
pressed by NK cells and other subpopulations of lymphocytes.
In addition to the effects of iNKT cells on positive regulators of
transactivation, we also observed reciprocal effects on PD-1
ligands that are negative regulators of immune responses.
Most studies have shown PD-L1 to be the dominant interacting
partner for PD-1, and this interaction reduces TCR signaling by
initiating a dephosphorylation cascade (Keir et al., 2008).
Although previous studies have found evidence for effects of
both PD-L1 and PD-L2 on glycolipid-induced iNKT cell re-
sponses (Singh et al., 2011), we observed significant effects on
such responses in Pdcd1lg2/ but not in Pdcd1lg1/ mice.
Taken together, the strong and rapid upregulation of PD-L2
observed on APCs following recognition of Th2 cell-biasing gly-
colipids such as aGC C20:2, along with increased cytokine re-
sponses inPdcd1lg2/mice that lack PD-L2 protein, implicated
selective upregulation of PD-L2 on APCs as a mechanism to
restrain the transactivation of bystander cells. This mechanism
is likely to play a role in suppressing NK cell-mediated IFN-g pro-
duction, thereby reinforcing the cytokine profile induced by
glycolipid antigens that give a Th2 cell cytokine bias.
In summary, our results demonstrate a predominant role for
the CD8a+ DC subset in presentation of a variety of glycolipid
antigens, including examples of those that elicit markedly
different patterns of cytokines. Rather than supporting the
hypothesis that presentation by different types of APCs is the
major mechanism responsible for the divergent responses to
various glycolipids, our results suggest that these responses
are regulated mainly by a mechanism intrinsic to CD8a+ DCs
that determines the extent to which NK cells and other leuko-
cytes are rapidly transactivated. This mechanism is controlled
by iNKT cells through their recognition of CD1d-presented gly-
colipids on CD8a+ DCs, and involves modulation of the land-
scape of cell surface costimulatory and coinhibitory molecules
expressed by these DCs in a manner that is dependent on the
fine structure of glycolipid antigens. Although the details of the
signaling processes through which iNKT cells modulate CD8a+
DC functions remain to be determined, further studies of this pro-
cess should facilitate the application of glycolipid activators of
iNKT cells as vaccine adjuvants or in other types of immunother-
apeutic interventions.EXPERIMENTAL PROCEDURES
Mice
Mice were maintained under specific pathogen-free conditions and used at
6–8 weeks of age. The CD279/, Pdcd1lg1/, and Pdcd1lg2/ mice were
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son Laboratories. For S. pneumoniae infection studies, Batf3/ and control
WT mice were 129SJ background. All other mice were backcrossed to
C57BL/6 for R10 generations. Blood samples were collected at 2, 12, and
24 hr after APC transfer or glycolipid administration. For IL-12 analysis, sam-
ples were collected at 8 hr after glycolipid administration. All procedures
involving animals were approved by the Institutional Animal Care and Use
Committee.
Reagents, Antibodies, and Glycolipids
Chemical reagents were purchased from Sigma-Aldrich unless specified
otherwise. The mAb L363, specific for the complex composed of mCD1d
with a bound aGC glycolipid, was produced in our laboratory (Yu et al.,
2007) and conjugated to Alexa Fluor 647 (Invitrogen). Fluorochrome conju-
gates of mAbs specific for cell markers and cytokines were purchased from
BD Biosciences, eBiosciences, and Invitrogen. The anti-CD70 mAb used for
in vivo blocking studies (TAN1-7) is a rat IgG2a that was generated by standard
fusion techniques following immunization with soluble recombinant mouse
CD70-Fc fusion protein (A.A.-S., unpublished data). Mice received 200 mg
i.v. of anti-CD70 or isotype-matched control antibody 16 hr before glycolipid
administration. Glycolipids were synthesized and prepared as 20 mMsolutions
for injection in vehicle (PBS + 0.1% DMSO + 0.05% Tween-20) as described
previously (Im et al., 2009; Tyznik et al., 2011). Mice were injected i.p. with
0.1 ml of these solutions for a glycolipid dose of 2 nM. b-glucosylceramide
(C18 sphingosine and C24:1 acyl group) was purchased from Avanti. For
in vitro assays, glycolipids were dissolved in 100% DMSO at 500 mM, briefly
sonicated, and then diluted directly into prewarmed (37C) culture medium.
Cell Culture
Tissue culture reagents were purchased from Invitrogen. Cells were cultured in
U bottom 96-well plates at a density of 2.5 3 105 cells per well in complete
RPMI-1640 media containing 10% FBS. For the cell-depletion assays, splenic
cells were cultured with a range of different glycolipid concentrations after
mock, CD11c, CD19, or F4/80 depletion. Biotinylated monoclonal antibodies
specific for CD11c, F4/80, CD19 or NK1.1, and anti-biotin magnetic beads
(Miltenyi) were used for depletion or enrichment experiments. For the in vitro
APC potency assays, isolated cells were pulsed with range of glycolipid con-
centration for 1 hr, washed 5 times with PBS, and cocultured with NK1.1+ cells
for 16 hr. Supernatants were analyzed for secreted IFN-g and IL-4 by using
capture ELISA as described previously (Im et al., 2009; Tyznik et al., 2011).
Bacterial Infections
The Streptococcus pneumoniae URF918 strain was obtained from Dr. M. Kro-
nenberg. Bacterial cultures were grown in Todd-Hewitt Broth media at 37C
with 5%CO2 tomid log phase as described (Kinjo et al., 2011). Mice were inoc-
ulated intranasally with 13 106 colony forming units of S. pneumoniae. Murine
lungs and spleens were harvested 48 or 72 hr after infection, and bacterial bur-
dens were estimated by plating the tissue homogenates on blood agar media
plates. Incorporation of glycolipids into BCG was performed as described
earlier (Venkataswamy et al., 2009) with minor modifications.
Flow Cytometry
Spleen and lung tissuesweremincedwith a scalpel and digested with Liberase
and DNase, and passed through a 70 mm filter to generate single cell suspen-
sions. For intracellular staining, the cells were stained with antibodies to cell
surface markers before fixation with 2% paraformaldehyde. Cells were then
treated with permeabilization buffer (1% BSA, 0.1% sodium azide, 0.05%
glycine, and 0.05% Triton X-100), then blocked with 10% mouse serum and
finally stained for 15 min on ice with antibodies to specific cytokines. Samples
were analyzed with FACSCalibur, FACSCanto II, or LSR II cytometers and
sorted with a FACSAria cell sorter (BD Biosciences).
Immunofluorescence Microscopy
Fixed and sucrose impregnated tissues were embedded in OTC freezing
media for cryosectioning. The frozen sections were permeabilized with 0.5%
saponin, blocked with 10% mouse serum, and stained with appropriate
antibodies. After washing, the sections were mounted with ProLong Gold
(Invitrogen). Confocal images were acquired with a Leica SP5 AOBS (LeicaMicrosystems). Image analysis and calculation of Pearson correlation coeffi-
cients (R2) to assess colocalization of fluorescent signals were done with
ImageJ software (Schneider et al., 2012).
In Vivo APC Transfer Assays
For cell transfers, CD19+, CD11c+, and CD8+ DC isolation reagents (Miltenyi)
were used to enrich the cell populations from naive murine splenocytes.
For isolation of monocytes and neutrophils, splenocytes were depleted of
CD19+ cells and sorted after staining for CD11b, Ly6C, and Ly6G on a
FACSAria cell sorter. All isolated subsets used for experiments were of
>95% purity. After enrichment, cells were pulsed with 100 nM glycolipid in
complete RPMI-1640 media for 1 hr, washed 5 times with PBS and counted
for live cells with trypan blue exclusion. One million cells were injected intrave-
nously in 0.2 ml volume. For the dendritic cell adoptive transfer experiments,
CD11c+ cells were purified from WT and Cd1d/ animals by using anti-
CD11c magnetic beads (Miltenyi Biotech), labeled with CFSE and injected
i.v. an hour before glycolipid administration.
Statistical Analysis
Student’s t test was used for comparisons involving two groups. One way
ANOVA with Dunnet’s correction was used for comparing groups of three or
more when there was only one independent variable. Two-way ANOVA with
Holm-Sidak correction was used to analyze the effect of glycolipid treatment
and BatF3 deletion as two independent factors. Statistical tests were per-
formed with Prism 6 software (GraphPad).
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